Jagsonpal Pharmaceuticals Limited shares surged nearly 6% on January 23, 2025, following the announcement of its robust Q3 FY25 financial performance. The stock traded at ₹241, up by ₹12.75, reflecting a 5.59% increase from its previous close of ₹228.25.
Key Financial Highlights:
- Revenue: The company reported a revenue of ₹740 million for Q3 FY25, marking a 57% year-on-year (YoY) growth compared to ₹472 million in Q3 FY24.
- Operating EBITDA: The operating EBITDA stood at ₹171 million, reflecting an impressive 183% YoY growth, with a margin expansion to 23.1% from 12.8% in Q3 FY24.
- Business PAT: Net profit (PAT) for Q3 FY25 surged by 183% YoY to ₹115 million.
Nine-Month Performance:
- Revenue: For the nine months ended December 31, 2024, the company reported ₹2,102 million, a 27% YoY growth.
- EBITDA: Operating EBITDA for the period stood at ₹482 million, growing 53% YoY with a margin of 22.9%.
- Strong Balance Sheet: The sale of the Faridabad facility for ₹410 million boosted the company’s cash balance to ₹1,321 million as of December 31, 2024.
Strategic Achievements:
- The integration of its recently acquired business has progressed as planned, contributing positively to the quarterly results.
- The company’s strategic moves and strong operational execution have resulted in significant margin improvements and a robust financial position.
Manish Gupta, Managing Director and CEO of Jagsonpal Pharmaceuticals, expressed confidence in the company’s growth trajectory, highlighting the effective alignment of operations with market opportunities.
